Multiple Lytic Lesions on F-18 Fluorodeoxyglucose Positron
Emission Tomography/Computed Tomography not Always Metastatic? Figure 1 : F-18 fluorodeoxyglucose positron emission tomography/computed tomography maximum intensity projection image (a) and fused positron emission tomography/computed tomography and computed tomography images at neck (b and c) soft-tissue density nodule posterior to left lobe of thyroid with no significant fluorodeoxyglucose uptake (thick white arrow) and multiple lytic lesions as shown in fused positron emission tomography/computed tomography axial sections at pelvis (d) with no significant uptake (small white arrow) and at knee level (e) with increased fluorodeoxyglucose uptake (white arrow) Primary hyperparathyroidism characterized by elevated serum PTH due to hyperfunctioning parathyroid glands manifests as hypercalcemia due to abnormal bone metabolism and brown tumors. [1, 2] Brown tumors are non-neoplastic and are due to high osteoclastic activity leading to bone resorption. [1] The sensitivities of Tc99 m MIBI scintigraphy, ultrasound, and combined techniques have been reported to be about 85.3%, 72.5%, and 90.4%, respectively. [3] Parathyroid surgery is the only definitive cure for primary and tertiary hyperparathyroidism. [4] Cases has been reported in which patients diagnosed with brown tumors have resolved after successful parathyroidectomy due to mineralization of the brown tumors after normalization of the serum calcium and PTH levels. [5] This case demonstrates how biochemical evaluation of calcium, phosphorus, and PTH changed the whole management in the light of F-18 FDG PET/CT findings.
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Sir, A 26-year-old female presented with complaints of pain in the left knee since 2 years and right arm pain and swelling for 2 weeks. The patient had a history of fall 2 months ago. Radiographs of the arm and thigh revealed lytic lesions in mid shaft of right humerus associated with pathological fracture and lytic lesion in the left femoral shaft. The patient was referred for an F-18 fluorodeoxyglucose positron emission tomography/computed tomography scan (F-18 FDG PET/CT) which revealed lytic lesions with variable FDG uptake involving extensive skeletal sites associated with pathological fractures [ Figure 1 ]. Generalized osteopenia was also noted. In addition to this, a well-defined soft tissue density nodule measuring 2.1 cm × 1.6 cm was seen posterior to lower pole of left thyroid lobe which showed low FDG uptake [ Figure 1b and c]. Based on the above findings, serum calcium and serum parathyroid hormone (PTH) levels were sought. Due to elevated serum calcium, serum PTH levels, multiple lytic lesions with pathological fractures and diffuse osteopenia, a clinical suspicion of parathyroid adenoma arose. Subsequently, the patient underwent Technetium 99 m sestamibi scan (Tc99m MIBI) which revealed a left-sided parathyroid adenoma [ Figure 2 ]. Although F18 FDG PET/CT is routinely used for investigating multiple lytic lesions, this is an important example of how a biochemical screening could have changed the diagnostic algorithm. A simple endocrine evaluation thus eventually resulted in guiding a definitive surgical cure for the patient. This patient underwent surgery and histopathology confirmed a parathyroid adenoma.
Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report
Sir, Insulin neutral protamine Hagedorn (NPH) and detemir have been approved for use in pregnancy as basal insulin. These insulins do not have any adverse maternal or fetal effects. Studies have shown comparable results with similar insulin doses in women with type 1 diabetes but higher insulin detemir dose was required to achieve similar glycemic control among patients with type 2 diabetes. We report case of a pregnant female with diabetes, who had high fasting blood sugar (108-131mg/dL) at very high dose of insulin detemir (48 IU/day) but was controlled on relatively lesser dose of traditional insulin NPH (40 IU/day). So, clinicians should be aware of potentially increased insulin dose requirement while prescribing insulin detemir to pregnant patients with diabetes. Also, changes in basal insulin dose should be anticipated when switching from insulin detemir to insulin NPH. This case brings forward reduced efficacy of insulin detemir as an important aspect of treating diabetes with pregnancy. If fasting blood sugar is still high on a reasonable dose of insulin detemir, shifting to insulin NPH with dose adjustment may be considered.
Historically, insulin NPH, along with short-acting insulin, is used for the treatment of diabetes during pregnancy. Due to 16-18 h duration of action, it is not a true once-daily basal insulin. Night-time administration of insulin NPH increases the risk of early morning hypoglycemia. It needs to be resuspended adequately before injection to prevent inaccurate dosing and risk of hyper-and hypo-glycemia. [1] Its action profile does not mimic physiology and this pharmacokinetics makes aggressive glycemic control difficult, which may result poor maternofetal outcome. Insulin analogs overcome these pharmacokinetic limitations. Insulin detemir, a long-acting recombinant human insulin analog, has not shown to have adverse maternal or fetal effects. It has been approved for use in pregnancy by the United States Food and Drug Administration. [2] [3] [4] A head-to-head comparison between insulin detemir and NPH in pregnant women with type 1 diabetes has shown that FBS improved with insulin detemir, without an increased incidence of hypoglycemia with no difference in fetal outcome, while the mean dose was same for both insulins. [2] However, other studies have found a higher insulin detemir dose requirement as compared to other basal insulins to achieve similar glycemic control among patients with type 2 diabetes. [5, 6] We report an interesting case of a female with pregnancy and diabetes, who had high FBS at very high dose of insulin detemir but was controlled on relatively lesser dose of traditional insulin NPH.
A 35-year-old pregnant female consulted us for better glycemic control during the first trimester of pregnancy. She was diagnosed to have diabetes a week before
